Daniel Hayes, MD, explains the implementation of the American Society of Clinical Oncology's CancerLinQ for beta testing.
Moderator Surabhi Dangi-Garimella asked Daniel Hayes, MD, who has been elected president of the American Society of Clinical Oncology (ASCO) for the term beginning in June 2016, what changes practices would have to adopt to implement ASCO’s CancerLinQ.
Currently, ASCO is rolling out CancerLinQ for beta testing in a number of practices, but he admits they don’t really know how it will function until they put it to work.
“I think as it becomes increasingly more successful, other practices will see the advantages of being enrolled,” he said.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More